A Geelong mum-of-three has searched far and wide for a uniform her eczema-suffering son can wear without triggering painful ...

Kyowa Kirin will file for rocatinlimab’s US approval, which was once Amgen’s most late-stage pipeline candidate.

Sanofi said its amlitelimab drug confirmed its potential to treat eczema in patients 12 years and older in two late-phase ...

Jia Patrick told Newsweek that living with TSW has been "a truly harrowing experience" that will take a long time to recover ...

Sanofi (EPA: SASY) has announced encouraging late-stage clinical trial results for its investigational drug amlitelimab, ...

The two-time U.S. Olympic gold medalist gymnast opens up about her skin condition, her fashion dos and don’ts for eczema, and ...

We recently published 10 Stocks With Effortless Double-, Triple-Digit Gains. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was ...

Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious ...

Investing.com -- Sanofi (EPA:SASY) announced Friday that its amlitelimab drug demonstrated positive results in two late-phase ...

We recently published 10 Big Names Stumbling Hard. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was one of the worst performers ...

Topline data were announced from two phase 3 trials evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.

“Whilst most cases of impetigo are not serious and can heal on their own, leaving impetigo untreated can lead to more serious ...